In a pregnant woman at 28 weeks, should anti‑D immunoglobulin be administered if the indirect Coombs test (ICT) is positive, and should it be given if the ICT is negative?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Anti-D Administration at 28 Weeks Based on Indirect Coombs Test Results

If the indirect Coombs test (ICT) is negative at 28 weeks, you should give anti-D immunoglobulin; if the ICT is positive at 28 weeks, you should still give anti-D immunoglobulin unless the woman is already alloimmunized (has true anti-D antibodies from prior sensitization).

Understanding the Clinical Scenario

The indirect Coombs test status at 28 weeks determines your interpretation, not your decision to give prophylaxis:

When ICT is Negative at 28 Weeks

  • Give anti-D immunoglobulin routinely at 28 weeks' gestation to all RhD-negative, non-sensitized women carrying an RhD-positive fetus (or when fetal blood type is unknown) 1.
  • This antenatal prophylaxis reduced alloimmunization rates by 90% when added to postpartum-only programs, decreasing fetal mortality from Rh hemolytic disease from 120 per 100,000 live births to 1.5 per 100,000 1.
  • The standard dose is 300 μg (1500 IU) intramuscularly or intravenously 2.

When ICT is Positive at 28 Weeks

This requires careful interpretation because a positive ICT at 28 weeks can mean two very different things:

Scenario 1: Passive Anti-D from Prior Prophylaxis

  • If the woman received anti-D for a sensitizing event earlier in pregnancy (bleeding, trauma, invasive procedure), the ICT will be positive from the passive antibodies you gave her 3, 4.
  • These passive antibodies are detectable by ICT in 85-97% of women for 4-11 weeks after administration, with titers typically ≤1:8 to 1:16 3.
  • In this case, still give the routine 28-week dose because passive antibodies wane over time, and you need coverage through delivery 3, 2.

Scenario 2: True Alloimmunization (Sensitization)

  • If the woman has developed true anti-D antibodies from prior sensitization (failed prophylaxis, missed dose, or sensitization before prophylaxis was available), the ICT will also be positive.
  • In this case, anti-D prophylaxis is futile because she is already producing her own antibodies—the horse has left the barn.
  • However, she requires specialized fetal medicine monitoring for hemolytic disease of the fetus and newborn (HDFN) with serial middle cerebral artery Doppler assessments 5, 6.

How to Distinguish Between Passive and Active Antibodies

Key distinguishing features:

  1. Timing and History

    • Review whether anti-D was given earlier in pregnancy (first trimester bleeding, trauma, amniocentesis, etc.)
    • If yes, and the ICT is positive within 4-11 weeks of that dose, it's likely passive antibodies 3
  2. Antibody Titer

    • Passive anti-D from prophylaxis typically produces titers ≤1:8 by standard ICT or ≤1:16 by more sensitive methods 3
    • True alloimmunization often produces higher and rising titers, though this is not absolute
  3. Serial Testing

    • Passive antibodies decline over weeks; true alloimmunization shows stable or rising titers
    • If uncertain, repeat testing in 2-4 weeks can clarify
  4. Clinical Context

    • First pregnancy with no prior sensitizing events = passive antibodies more likely if anti-D was given
    • History of prior RhD-positive pregnancy without adequate prophylaxis = true alloimmunization more likely

The Critical Clinical Algorithm

At 28 weeks' gestation in an RhD-negative woman:

  1. Check antibody screen (ICT) at 28 weeks 5, 2

  2. If ICT is negative:

    • Give anti-D 300 μg immediately
    • No further investigation needed
  3. If ICT is positive:

    • Review history: Was anti-D given earlier in this pregnancy?
      • If YES (within past 4-11 weeks): Likely passive antibodies
        • Still give the 28-week dose 3, 2
        • Document that postpartum anti-D should still be given after delivery if baby is RhD-positive
      • If NO (no prior anti-D this pregnancy): Likely true alloimmunization
        • Do NOT give anti-D (ineffective once sensitized)
        • Obtain antibody identification and titer
        • Refer to maternal-fetal medicine for HDFN monitoring 5, 6
        • Begin serial MCA Doppler surveillance if titer is above critical threshold

Common Pitfalls to Avoid

Pitfall 1: Withholding 28-week anti-D because ICT is positive from earlier prophylaxis

  • This leaves the woman unprotected in late pregnancy when fetomaternal hemorrhage risk is highest (29% of pregnancies show fetal cells in maternal circulation in third trimester) 1.
  • Nearly two-thirds of women have undetectable anti-D at delivery when prophylaxis is given only at 28 weeks, especially if delivery occurs >10 weeks later 4, 7.

Pitfall 2: Assuming all positive ICT results at 28 weeks represent sensitization

  • This leads to unnecessary anxiety, inappropriate withholding of prophylaxis, and excessive fetal monitoring 3.

Pitfall 3: Failing to give postpartum anti-D after detecting passive antibodies

  • Even when anti-D is detectable at delivery from antenatal prophylaxis, postpartum anti-D must still be given if the baby is RhD-positive 3, 2.
  • The detectable antibodies may be insufficient to cover the larger fetomaternal hemorrhage that occurs at delivery (50% of postpartum patients have fetal cells in circulation) 1.

Pitfall 4: Not testing for fetomaternal hemorrhage volume at delivery

  • Standard 300 μg dose covers only 15 mL of fetal red blood cells (30 mL whole fetal blood) 2.
  • Larger hemorrhages (especially with placental abruption, trauma, or manual placental removal) require additional anti-D: 10 μg per additional 0.5 mL fetal RBCs 2, 8.

The Bottom Line for Clinical Practice

The indirect Coombs test at 28 weeks does not determine whether to give anti-D—it helps you interpret what a positive result means. Unless you can definitively establish true alloimmunization (no prior anti-D given this pregnancy + positive ICT), you should administer the routine 28-week prophylaxis dose. The stakes are too high: without adequate prophylaxis, 17% of RhD-negative women become alloimmunized, risking severe HDFN in future pregnancies with potential fetal hydrops, intrauterine transfusions, and fetal death 1.

References

Research

Prevention of Rh alloimmunization.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2003

Research

From prophylaxis to parturition: evaluating antibody screen reactivity following antenatal anti-D at 28 weeks.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.